In a filing, Rhythm Pharmaceuticals Inc revealed its Corporate Controller & CAO German Christopher Paul unloaded Company’s shares for reported $0.14 million on Jun 10 ’25. In the deal valued at $67.19 per share,2,069 shares were sold. As a result of this transaction, German Christopher Paul now holds 1,889 shares worth roughly $0.12 million.
Then, Cramer Pamela J. sold 7,031 shares, generating $478,435 in total proceeds. Upon selling the shares at $68.05, the Chief Human Resources Officer now owns 19,209 shares.
Before that, CHRISTOPHER PAUL GERMAN bought 2,069 shares. Rhythm Pharmaceuticals Inc shares valued at $138,044 were divested by the Officer at a price of $66.72 per share.
BofA Securities upgraded its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy from a a Neutral in a research note published recently. Jefferies began covering RYTM with “Buy” recommendation on January 02, 2025. Oppenheimer started covering the stock on December 20, 2024. It rated RYTM as “an Outperform”.
Price Performance Review of RYTM
On Tuesday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock fall -0.67% to $61.97. Over the last five days, the stock has lost -8.02%. Rhythm Pharmaceuticals Inc shares have risen nearly 10.70% since the year began. Nevertheless, the stocks have risen 39.67% over the past one year. While a 52-week high of $69.89 was reached on 06/09/25, a 52-week low of $39.46 was recorded on 04/07/25.
Levels Of Support And Resistance For RYTM Stock
The 24-hour chart illustrates a support level at 60.98, which if violated will result in even more drops to 59.98. On the upside, there is a resistance level at 62.79. A further resistance level may holdings at 63.60.
The most recent change occurred on October 21, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
